<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427841</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00011256</org_study_id>
    <secondary_id>NCI-2015-00498</secondary_id>
    <secondary_id>SOL-14124-L</secondary_id>
    <secondary_id>IRB00011256</secondary_id>
    <nct_id>NCT02427841</nct_id>
  </id_info>
  <brief_title>Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>Phase 2 Study of Preoperative Chemotherapy With Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well nab-paclitaxel and gemcitabine hydrochloride followed by&#xD;
      radiation therapy before surgery work in treating patients with pancreatic cancer that can be&#xD;
      removed by surgery. Chemotherapy drugs, such as nab-paclitaxel and gemcitabine hydrochloride,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells, by&#xD;
      stopping them from dividing, or by stopping them from spreading. Radiation therapy uses&#xD;
      high-energy x-rays to kill tumor cells and shrink tumors. Giving nab-paclitaxel, gemcitabine&#xD;
      hydrochloride, and radiation therapy before surgery may make the tumor smaller and reduce the&#xD;
      amount of normal tissue that needs to be removed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the R0 (complete resection) resection rate for subjects with borderline&#xD;
      resectable or lymph node positive pancreatic adenocarcinoma treated with a multimodality&#xD;
      neoadjuvant therapy of preoperative gemcitabine (gemcitabine hydrochloride) and ABRAXANE&#xD;
      (nab-paclitaxel) followed by 5-fluorouracil (fluorouracil) based image-guided&#xD;
      intensity-modulated radiation therapy (IG-IMRT) chemoradiotherapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine 1-year relapse-free survival rate with the investigational protocol.&#xD;
&#xD;
      II. To determine 1-year and 2-year overall survival rates. III. To assess response rate by&#xD;
      imaging (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) and pathologic analysis.&#xD;
&#xD;
      IV. To assess the toxicity and safety according to Common Terminology Criteria for Adverse&#xD;
      Events version 4.0 (CTCAE v4.0) criteria.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      PRE-OPERATIVE (NEOADJUVANT) CHEMOTHERAPY: Patients receive nab-paclitaxel intravenously (IV)&#xD;
      over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats&#xD;
      every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.&#xD;
      Beginning 3-6 weeks after completion of chemotherapy, patients undergo IG-IMRT 5 days a week&#xD;
      for 28 fractions and receive fluorouracil IV continuously on days 1-7 for 6 weeks.&#xD;
&#xD;
      SURGICAL RESECTION: Patients undergo surgery 4-10 weeks after the last dose of&#xD;
      chemoradiation.&#xD;
&#xD;
      POST-OPERATIVE (ADUJUVANT) CHEMOTHERAPY: Beginning within 8-12 weeks after surgery, patients&#xD;
      receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8,&#xD;
      and 15. Treatment repeats every 28 days for 4 additional courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 12 weeks for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 21, 2016</start_date>
  <completion_date type="Anticipated">March 12, 2022</completion_date>
  <primary_completion_date type="Actual">November 12, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0 Resection Rate Defined as Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins by Pathologic Assessment</measure>
    <time_frame>At the time of surgery</time_frame>
    <description>The R0 resection rate will be computed with 95% confidence interval. A 2-sided binomial test will be used to determine whether the R0 resection rate is significantly greater than 0.37 at 10% significance level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Toxicity According to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version (v) 4.0</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Frequency and severity of adverse events will be tabulated based on the actual treatment and the number of courses the patient receives. In particular, grade 3 and 4 toxicity rates will be computed and summarized for all patients received at least one dose of the assigned treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Defined as the Percentage of Subjects Alive at the 2 Year Time Point</measure>
    <time_frame>At 2 years</time_frame>
    <description>The expected 2-year overall survival rate will be reported with an associated 95% confidence interval. In addition, the overall survival function will be estimated and displayed using a Kaplan Meier curve. The median overall survival will also be estimated with an associated 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Defined as the Percentage of Subjects Alive at the One Year Time Point</measure>
    <time_frame>At 1 year</time_frame>
    <description>The expected 1-year overall survival rate will be reported with an associated 95% confidence interval. In addition, the overall survival function will be estimated and displayed using a Kaplan Meier curve. The median overall survival will also be estimated with an associated 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free Survival Defined as the Percentage of Subjects Who Are Without Recurrence or Death at One Year From Surgical Resection of the Primary Tumor</measure>
    <time_frame>At 1 year</time_frame>
    <description>The expected 1-year relapse-free survival rate will be reported with an associated 95% confidence interval. In addition, the relapse-free survival function will be estimated and displayed using a Kaplan Meier curve. The median relapse-free survival will also be estimated with an associated 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Defined as the Number of Subjects With Complete or Partial Disease Response as Confirmed Through Tumor Imaging With Computed Tomography (CT)</measure>
    <time_frame>After completion of neoadjuvant chemoradiotherapy</time_frame>
    <description>The expected pathologic response rate will be computed with the associated 95% confidence interval using binomial exact method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <condition>Resectable Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, chemoradiation therapy, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRE-OPERATIVE (NEOADJUVANT) CHEMOTHERAPY: Patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo IG-IMRT 5 days a week for 28 fractions and receive fluorouracil IV continuously on days 1-7 for 6 weeks.&#xD;
SURGICAL RESECTION: Patients undergo surgery 4-10 weeks after the last dose of chemoradiation.&#xD;
POST-OPERATIVE (ADUJUVANT) CHEMOTHERAPY: Beginning within 8-12 weeks after surgery, patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4 additional courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, chemoradiation therapy, surgery)</arm_group_label>
    <other_name>5-Fluoro-2,4(1H, 3H)-pyrimidinedione</other_name>
    <other_name>5-Fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
    <other_name>AccuSite</other_name>
    <other_name>Carac</other_name>
    <other_name>Fluoro Uracil</other_name>
    <other_name>Fluouracil</other_name>
    <other_name>Flurablastin</other_name>
    <other_name>Fluracedyl</other_name>
    <other_name>Fluracil</other_name>
    <other_name>Fluril</other_name>
    <other_name>Fluroblastin</other_name>
    <other_name>Ribofluor</other_name>
    <other_name>Ro 2-9757</other_name>
    <other_name>Ro-2-9757</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, chemoradiation therapy, surgery)</arm_group_label>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine</other_name>
    <other_name>Gemzar</other_name>
    <other_name>LY-188011</other_name>
    <other_name>LY188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Image Guided Radiation Therapy</intervention_name>
    <description>Undergo IG-IMRT</description>
    <arm_group_label>Treatment (chemotherapy, chemoradiation therapy, surgery)</arm_group_label>
    <other_name>IGRT</other_name>
    <other_name>image-guided radiation therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Undergo IG-IMRT</description>
    <arm_group_label>Treatment (chemotherapy, chemoradiation therapy, surgery)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy, chemoradiation therapy, surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, chemoradiation therapy, surgery)</arm_group_label>
    <other_name>ABI 007</other_name>
    <other_name>ABI-007</other_name>
    <other_name>Abraxane</other_name>
    <other_name>Albumin-bound Paclitaxel</other_name>
    <other_name>Albumin-Stabilized Nanoparticle Paclitaxel</other_name>
    <other_name>Nanoparticle Albumin-bound Paclitaxel</other_name>
    <other_name>nanoparticle paclitaxel</other_name>
    <other_name>paclitaxel albumin-stabilized nanoparticle formulation</other_name>
    <other_name>protein-bound paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Conventional Surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Treatment (chemotherapy, chemoradiation therapy, surgery)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have histologically or cytologically confirmed adenocarcinoma of the&#xD;
             pancreas&#xD;
&#xD;
          -  Tumors must be localized (non-metastatic) and classified as borderline resectable&#xD;
             according to Americas Hepato-Pancreato-Biliary Association (AHPBA)/Society of Surgical&#xD;
             Oncology (SSO)/Society for Surgery of the Alimentary Tract (SSAT) consensus criteria&#xD;
             or be clinically node-positive via computed tomography (CT) or endoscopic ultrasound&#xD;
&#xD;
               -  AHPBA/SSO/SSAT criteria (any one of the following):&#xD;
&#xD;
                    -  Tumor-associated deformity of the SMV (superior mesenteric vein) or PV&#xD;
                       (portal vein)&#xD;
&#xD;
                    -  Abutment of the SMV or PV &gt;= 180 degrees&#xD;
&#xD;
                    -  Short-segment occlusion of the SMV or PV amenable to resection and venous&#xD;
                       reconstruction&#xD;
&#xD;
                    -  Short-segment involvement of the hepatic artery or its branches amenable to&#xD;
                       resection and reconstruction&#xD;
&#xD;
                    -  Abutment of the superior mesenteric artery (SMA) &lt; 180 degrees&#xD;
&#xD;
          -  Subjects must have measurable disease (by RECIST 1.1), defined as at least one lesion&#xD;
             that can be accurately measured in at least one dimension (longest diameter to be&#xD;
             recorded for non-nodal lesions and short axis for nodal lesions) as &gt;= 20 mm with&#xD;
             conventional techniques or as &gt;= 10 mm with spiral CT scan&#xD;
&#xD;
          -  No prior therapy for pancreatic cancer, including chemotherapy, radiation therapy,&#xD;
             definitive surgery or investigational therapy&#xD;
&#xD;
          -  Members of all races and ethnic groups will be included&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1.5 K/cu mm&#xD;
&#xD;
          -  Platelets &gt;= 100 K/cu mm&#xD;
&#xD;
          -  Hemoglobin &gt;= 9.0 g/dL&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.25 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 2.5 x institutional upper limit of normal&#xD;
&#xD;
          -  Creatinine within normal institutional limits or creatinine clearance &gt;= 60 mL/min&#xD;
&#xD;
          -  No active prior malignancy within 3 years of registration (with the exception of&#xD;
             non-melanoma skin cancer, in-situ cancers, or Rai stage 0 chronic lymphocytic leukemia&#xD;
             [CLL]); if patient is disease free from a prior malignancy between 3-5 years, special&#xD;
             consideration can be requested; in these cases, if the risk of recurrence at 5 years&#xD;
             is less than 20%, and in the opinion of the investigator the prior malignancy will not&#xD;
             affect the patient's outcome in light of newly diagnosed pancreatic cancer, the&#xD;
             patient may be eligible; this will require principle investigator (PI) review and&#xD;
             approval on a case by case basis, and approval will be documented in the medical&#xD;
             record; all patients who have been disease free from a prior malignancy for at least 5&#xD;
             years will be eligible&#xD;
&#xD;
          -  No baseline peripheral sensory neuropathy &gt;= grade 2&#xD;
&#xD;
          -  Women of child-bearing potential and men must be willing to use adequate contraception&#xD;
             during the entire study and for 8 weeks following completion of all chemotherapy on&#xD;
             study; this includes hormonal or barrier method, or abstinence&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with locally advanced, unresectable primary tumors will not be eligible&#xD;
&#xD;
               -  This includes any of the following:&#xD;
&#xD;
                    -  Abutment of the SMA &gt;= 180 degrees&#xD;
&#xD;
                    -  Occlusion of the SMV or PV with insufficient normal vein above and below&#xD;
                       with which to perform venous reconstruction&#xD;
&#xD;
                    -  Involvement of the hepatic artery with insufficient artery proximal and&#xD;
                       distal to perform reconstruction&#xD;
&#xD;
          -  Any prior therapy (chemotherapy, radiation or surgery) for pancreatic adenocarcinoma&#xD;
             other than biliary decompression&#xD;
&#xD;
          -  Subjects who are receiving any other investigational agents&#xD;
&#xD;
          -  Subjects with known metastases&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to ABRAXANE or other agents used in the study&#xD;
&#xD;
          -  Active infection requiring intravenous antibiotics at the time of registration&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  History of interstitial lung disease, idiopathic pulmonary fibrosis, silicosis,&#xD;
             sarcoidosis or connective tissue disorders (including rheumatoid arthritis and&#xD;
             systemic lupus erythematosus)&#xD;
&#xD;
          -  Pregnant or breastfeeding women are excluded from this study&#xD;
&#xD;
          -  Subjects known to be human immunodeficiency virus (HIV)-positive, including those on&#xD;
             combination antiretroviral therapy, are ineligible because of the potential for&#xD;
             pharmacokinetic interactions with chemotherapy; in addition, these subjects are at&#xD;
             increased risk of lethal infections when treated with marrow-suppressive therapy&#xD;
&#xD;
          -  Subjects with plastic biliary stents will be excluded; metal biliary stents are&#xD;
             allowed and will not be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gina Vaccaro</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 17, 2015</study_first_submitted>
  <study_first_submitted_qc>April 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2015</study_first_posted>
  <results_first_submitted>October 26, 2020</results_first_submitted>
  <results_first_submitted_qc>January 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2021</results_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Gina Vaccaro</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02427841/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>20 participants enrolled who agreed to participate in the study following completion of the informed consent process. 19 started is the number of participants who were assigned to each Arm/Group. One subject withdrew prior to treatment resulting in a total of 19 subjects enrolled and started treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Chemotherapy, Chemoradiation Therapy, Surgery)</title>
          <description>PRE-OPERATIVE (NEOADJUVANT) CHEMOTHERAPY: Patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo IG-IMRT 5 days a week for 28 fractions and receive fluorouracil IV continuously on days 1-7 for 6 weeks.&#xD;
SURGICAL RESECTION: Patients undergo surgery 4-10 weeks after the last dose of chemoradiation.&#xD;
POST-OPERATIVE (ADUJUVANT) CHEMOTHERAPY: Beginning within 8-12 weeks after surgery, patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4 additional courses in the absence of disease progression or unacceptable toxicity.&#xD;
Fluorouracil: Given IV&#xD;
Gemcitabine: Given IV&#xD;
Image Guided Radiation Therapy: Undergo IG-IMRT&#xD;
Intensity-Modulated Radiation Therapy: Undergo IG-IMRT&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Nab-paclitaxel: Given IV&#xD;
Therapeutic Conventional Surgery: Undergo surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Chemotherapy, Chemoradiation Therapy, Surgery)</title>
          <description>PRE-OPERATIVE (NEOADJUVANT) CHEMOTHERAPY: Patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo IG-IMRT 5 days a week for 28 fractions and receive fluorouracil IV continuously on days 1-7 for 6 weeks.&#xD;
SURGICAL RESECTION: Patients undergo surgery 4-10 weeks after the last dose of chemoradiation.&#xD;
POST-OPERATIVE (ADUJUVANT) CHEMOTHERAPY: Beginning within 8-12 weeks after surgery, patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4 additional courses in the absence of disease progression or unacceptable toxicity.&#xD;
Fluorouracil: Given IV&#xD;
Gemcitabine: Given IV&#xD;
Image Guided Radiation Therapy: Undergo IG-IMRT&#xD;
Intensity-Modulated Radiation Therapy: Undergo IG-IMRT&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Nab-paclitaxel: Given IV&#xD;
Therapeutic Conventional Surgery: Undergo surgery</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="42" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)</title>
          <description>Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) A scale used to describe a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability (walking, working, etc.). Scale ranges from 0 = Fully active, able to carry out all pre-disease performance without restriction to 5 = Dead.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0: Fully Active</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1: Restricted in physically strenuous activity but ambulatory and able to carry out light work</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary tumor site</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Head</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Body or neck</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Tail</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Greatest Tumor diameter</title>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" lower_limit="2.0" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vascular involvement</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Both arterial and venous</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Arterial only</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Venous only</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No vascular involvement</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lymph node status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive nodes on CT scan</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative nodes on CT scan</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum CA 19-9</title>
          <units>U/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="231" lower_limit="4" upper_limit="12,414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>R0 Resection Rate Defined as Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins by Pathologic Assessment</title>
        <description>The R0 resection rate will be computed with 95% confidence interval. A 2-sided binomial test will be used to determine whether the R0 resection rate is significantly greater than 0.37 at 10% significance level.</description>
        <time_frame>At the time of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Chemoradiation Therapy, Surgery)</title>
            <description>PRE-OPERATIVE (NEOADJUVANT) CHEMOTHERAPY: Patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo IG-IMRT 5 days a week for 28 fractions and receive fluorouracil IV continuously on days 1-7 for 6 weeks.&#xD;
SURGICAL RESECTION: Patients undergo surgery 4-10 weeks after the last dose of chemoradiation.&#xD;
POST-OPERATIVE (ADUJUVANT) CHEMOTHERAPY: Beginning within 8-12 weeks after surgery, patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4 additional courses in the absence of disease progression or unacceptable toxicity.&#xD;
Fluorouracil: Given IV&#xD;
Gemcitabine: Given IV&#xD;
Image Guided Radiation Therapy: Undergo IG-IMRT&#xD;
Intensity-Modulated Radiation Therapy: Undergo IG-IMRT&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Nab-paclitaxel: Given IV&#xD;
Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
        </group_list>
        <measure>
          <title>R0 Resection Rate Defined as Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins by Pathologic Assessment</title>
          <description>The R0 resection rate will be computed with 95% confidence interval. A 2-sided binomial test will be used to determine whether the R0 resection rate is significantly greater than 0.37 at 10% significance level.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.018</p_value>
            <p_value_desc>Standard R0 rate is 37%.</p_value_desc>
            <method>2-sided binomial</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Toxicity According to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version (v) 4.0</title>
        <description>Frequency and severity of adverse events will be tabulated based on the actual treatment and the number of courses the patient receives. In particular, grade 3 and 4 toxicity rates will be computed and summarized for all patients received at least one dose of the assigned treatment.</description>
        <time_frame>Up to 5 years</time_frame>
        <posting_date>11/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Defined as the Percentage of Subjects Alive at the 2 Year Time Point</title>
        <description>The expected 2-year overall survival rate will be reported with an associated 95% confidence interval. In addition, the overall survival function will be estimated and displayed using a Kaplan Meier curve. The median overall survival will also be estimated with an associated 95% confidence interval.</description>
        <time_frame>At 2 years</time_frame>
        <posting_date>11/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Defined as the Percentage of Subjects Alive at the One Year Time Point</title>
        <description>The expected 1-year overall survival rate will be reported with an associated 95% confidence interval. In addition, the overall survival function will be estimated and displayed using a Kaplan Meier curve. The median overall survival will also be estimated with an associated 95% confidence interval.</description>
        <time_frame>At 1 year</time_frame>
        <posting_date>11/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse-free Survival Defined as the Percentage of Subjects Who Are Without Recurrence or Death at One Year From Surgical Resection of the Primary Tumor</title>
        <description>The expected 1-year relapse-free survival rate will be reported with an associated 95% confidence interval. In addition, the relapse-free survival function will be estimated and displayed using a Kaplan Meier curve. The median relapse-free survival will also be estimated with an associated 95% confidence interval.</description>
        <time_frame>At 1 year</time_frame>
        <posting_date>11/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Defined as the Number of Subjects With Complete or Partial Disease Response as Confirmed Through Tumor Imaging With Computed Tomography (CT)</title>
        <description>The expected pathologic response rate will be computed with the associated 95% confidence interval using binomial exact method.</description>
        <time_frame>After completion of neoadjuvant chemoradiotherapy</time_frame>
        <posting_date>11/2021</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected at each investigator office visit from start to conclusion of subject's trial period. (up to 5 years). Utilizing NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0).</time_frame>
      <desc>Regular investigator assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Chemotherapy, Chemoradiation Therapy, Surgery)</title>
          <description>PRE-OPERATIVE (NEOADJUVANT) CHEMOTHERAPY: Patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo IG-IMRT 5 days a week for 28 fractions and receive fluorouracil IV continuously on days 1-7 for 6 weeks.&#xD;
SURGICAL RESECTION: Patients undergo surgery 4-10 weeks after the last dose of chemoradiation.&#xD;
POST-OPERATIVE (ADUJUVANT) CHEMOTHERAPY: Beginning within 8-12 weeks after surgery, patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4 additional courses in the absence of disease progression or unacceptable toxicity.&#xD;
Fluorouracil: Given IV&#xD;
Gemcitabine: Given IV&#xD;
Image Guided Radiation Therapy: Undergo IG-IMRT&#xD;
Intensity-Modulated Radiation Therapy: Undergo IG-IMRT&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Nab-paclitaxel: Given IV&#xD;
Therapeutic Conventional Surgery: Undergo surgery</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Intractable Nausea, vomiting, abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall soft tissue infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Fascial Dehiscene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>GDA Bleed/Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated liver function tests</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gina Vaccaro</name_or_title>
      <organization>OHSUKCI</organization>
      <phone>503-216-6300</phone>
      <email>vaccarog@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

